• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
[Oral anticoagulation treatment in patients with non-valvular auricular fibrillation].非瓣膜性心房颤动患者的口服抗凝治疗
Aten Primaria. 2002 Sep 30;30(5):284-9. doi: 10.1016/s0212-6567(02)79029-x.
2
Profiling of patients with non-valvular atrial fibrillation and moderate-to-high risk of stroke not receiving oral anticoagulation in Spain.西班牙未接受口服抗凝治疗的非瓣膜性心房颤动且中风风险为中到高危患者的特征分析。
Semergen. 2019 Sep;45(6):396-405. doi: 10.1016/j.semerg.2018.10.005. Epub 2018 Dec 17.
3
Stroke Risk Status, Anticoagulation Treatment, and Quality-of-Life in Chinese Patients with Atrial Fibrillation: China Registry of Atrial Fibrillation (CRAF).中国心房颤动患者的卒中风险状况、抗凝治疗和生活质量:中国心房颤动注册研究(CRAF)。
Cardiovasc Ther. 2019 Mar 21;2019:7372129. doi: 10.1155/2019/7372129. eCollection 2019.
4
Clinical Characteristics And Health Care Resources In Patients Treated With Oral Anticoagulants: Evidences From Italian Administrative Databases.接受口服抗凝剂治疗患者的临床特征与医疗资源:来自意大利行政数据库的证据
Vasc Health Risk Manag. 2019 Oct 11;15:429-437. doi: 10.2147/VHRM.S216749. eCollection 2019.
5
Comparative effectiveness of novel oral anticoagulants in UK patients with non-valvular atrial fibrillation and chronic kidney disease: a matched cohort study.新型口服抗凝药在英国非瓣膜性心房颤动合并慢性肾脏病患者中的比较疗效:一项匹配队列研究
BMJ Open. 2018 Jan 24;8(1):e019638. doi: 10.1136/bmjopen-2017-019638.
6
'Real-world' antithrombotic treatment in atrial fibrillation: The EORP-AF pilot survey.“真实世界”的心房颤动抗栓治疗:EORP-AF 初步调查。
Am J Med. 2014 Jun;127(6):519-29.e1. doi: 10.1016/j.amjmed.2013.12.022. Epub 2014 Jan 28.
7
[Differences in the management of patients with atrial fibrillation according to whether primary care or the specialist initiates treatment with direct oral anticoagulants. The SILVER-AP and BRONCE-AP studies].
Semergen. 2018 Jul-Aug;44(5):323-334. doi: 10.1016/j.semerg.2017.09.005. Epub 2017 Nov 27.
8
Antithrombotic treatment and characteristics of elderly patients with non-valvular atrial fibrillation hospitalized at Internal Medicine departments. NONAVASC registry.内科住院的老年非瓣膜性心房颤动患者的抗栓治疗及特征。非血管注册研究。
Med Clin (Barc). 2017 Mar 3;148(5):204-210. doi: 10.1016/j.medcli.2016.10.042. Epub 2016 Dec 16.
9
Current status and factors influencing oral anticoagulant therapy among patients with non-valvular atrial fibrillation in Jiangsu province, China: a multi-center, cross-sectional study.中国江苏省非瓣膜性心房颤动患者口服抗凝治疗的现状及影响因素:一项多中心、横断面研究。
BMC Cardiovasc Disord. 2020 Jan 16;20(1):22. doi: 10.1186/s12872-020-01330-6.
10
Large variations in the use of oral anticoagulants in stroke patients with atrial fibrillation: a Swedish national perspective.瑞典全国视角下房颤卒中患者口服抗凝药使用情况的巨大差异
J Intern Med. 2004 Jan;255(1):22-32. doi: 10.1046/j.0954-6820.2003.01253.x.

引用本文的文献

1
[The management of atrial fibrillation and characteristics of its current care in outpatients. AFABE observational study].[心房颤动的管理及其门诊当前护理特征。AFABE观察性研究]
Aten Primaria. 2014 Feb;46(2):58-67. doi: 10.1016/j.aprim.2013.06.003. Epub 2013 Sep 14.
2
[Characteristics of oral anti-coagulation treatment in high-risk chronic auricular fibrillation].[高危慢性心房颤动患者口服抗凝治疗的特点]
Aten Primaria. 2004 Nov 15;34(8):414-9. doi: 10.1016/s0212-6567(04)78925-8.
3
[Effectiveness of an intervention programme to improve oral anti-coagulation treatment for patients with chronic auricular fibrillation in a health district].[一项改善某健康区慢性心房颤动患者口服抗凝治疗的干预项目的效果]
Aten Primaria. 2002 Nov 30;30(9):588-9. doi: 10.1016/s0212-6567(02)79111-7.

本文引用的文献

1
Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation.非风湿性心房颤动患者长期抗凝或抗血小板治疗的系统评价
BMJ. 2001 Feb 10;322(7282):321-6. doi: 10.1136/bmj.322.7282.321.
2
[Prevention of thromboembolic disease in patients with heart disease].[心脏病患者血栓栓塞性疾病的预防]
Aten Primaria. 2000 Sep 30;26(5):293-7. doi: 10.1016/s0212-6567(00)78667-7.
3
[Atrial fibrillation and stroke].[心房颤动与中风]
Neurologia. 2000 Feb;15(2):51-7.
4
Decision analysis and guidelines for anticoagulant therapy to prevent stroke in patients with atrial fibrillation.心房颤动患者预防卒中的抗凝治疗决策分析与指南
Lancet. 2000 Mar 18;355(9208):956-62. doi: 10.1016/S0140-6736(00)90012-6.
5
[The use of anticoagulant treatment in patients with nonrheumatic atrial fibrillation].[非风湿性心房颤动患者抗凝治疗的应用]
Rev Esp Cardiol. 2000 Feb;53(2):200-4.
6
[Antithrombotic treatment in non-valvular atrial fibrillation].非瓣膜性心房颤动的抗栓治疗
Med Clin (Barc). 1999 Oct 2;113(10):397-8.
7
[Chronic atrial fibrillation and anticoagulant treatment].[慢性心房颤动与抗凝治疗]
Med Clin (Barc). 1999 Oct 2;113(10):397.
8
[Current status of oral anticoagulation control in primary care].
Aten Primaria. 1999 Jul-Aug;24(3):127-33.
9
[The use of antithrombotic drugs in patients with chronic atrial fibrillation in a local health area].[当地卫生区域慢性心房颤动患者抗血栓药物的使用情况]
Med Clin (Barc). 1999 Apr 10;112(12):454-6.
10
[Anticoagulant treatment: new aspects of an old therapy].[抗凝治疗:一种古老疗法的新进展]
Rev Clin Esp. 1999 Feb;199(2):89-94.

非瓣膜性心房颤动患者的口服抗凝治疗

[Oral anticoagulation treatment in patients with non-valvular auricular fibrillation].

作者信息

Arrojo Arias E, Mora Navarro G, Abón Santos A, Araujo Luis M S, Capdevila Gallego C, Gutiérrez Torres M J

机构信息

Médico de familia. EAP Orcasitas. Madrid. Spain.

出版信息

Aten Primaria. 2002 Sep 30;30(5):284-9. doi: 10.1016/s0212-6567(02)79029-x.

DOI:10.1016/s0212-6567(02)79029-x
PMID:12372209
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7684248/
Abstract

OBJECTIVES

To evaluate the knowledge, attitudes and difficulties of family doctors in the indication of oral anti-coagulation treatment (OCT) in patients with non-valvular auricular fibrillation (NVAF).

DESIGN

Transversal descriptive study.Setting. Area 11 of Madrid primary care.Participants. 250 doctors by simple randomised sampling.

MAIN MEASUREMENTS

After a pilot study at a health centre, mailing of a questionnaire with a subsequent re-mailing. This collected social and personal details, knowledge of the question, attitudes and difficulties.

RESULTS

157 (62.8%) replied; 91 were women (58.0%); mean age was 39 (SD, 6.0). 97 had reviewed the question recently (61.8%). 110 thought that the anti-aggregation criteria were clear (70.1%; CI, 62.2-77.0%), 107 that the oral anti-coagulation criteria were (68.2%; CI, 60.2-75.2%), 132 that the OCT risks were (84.1%; CI, 77.2-89.2%), and 74 that risk factors of cerebrovascular accident were clear (47.1%; CI, 39.2-55.2%). Initially 96 doctors gave anti-aggregants and referred to cardiology (61.1%; CI, 53.0-68.7%), and 29 began OCT (18.5%; CI, 12.9-25.6%). 134 thought that we avoided initiating OCT (85.3%; CI, 78.6-90.3%), giving as the main reasons the difficulty of monitoring and of requesting further tests, the risks involved and OCT not being up-to-date.

CONCLUSIONS

Most professionals have the criteria for OCT in NVAF clear, although they continue to avoid the initiation of OCT. The majority approach is to give anti-aggregants and refer to Cardiology, given the risk of the therapy and the difficulties involved in monitoring and requesting further tests.

摘要

目的

评估家庭医生在非瓣膜性心房颤动(NVAF)患者口服抗凝治疗(OCT)适应证方面的知识、态度及困难。

设计

横断面描述性研究。

背景

马德里初级保健第11区。

参与者

通过简单随机抽样选取250名医生。

主要测量指标

在一家健康中心进行预试验后,邮寄问卷并随后再次邮寄。问卷收集社会和个人详细信息、对该问题的了解、态度及困难。

结果

157人(62.8%)回复;91人为女性(58.0%);平均年龄为39岁(标准差6.0)。97人最近复习过该问题(61.8%)。110人认为抗聚集标准明确(70.1%;95%置信区间,62.2 - 77.0%),107人认为口服抗凝标准明确(68.2%;95%置信区间,60.2 - 75.2%),132人认为OCT风险明确(84.1%;95%置信区间,77.2 - 89.2%),74人认为脑血管意外危险因素明确(47.1%;95%置信区间,39.2 - 55.2%)。最初,96名医生给予抗聚集药物并转诊至心脏病科(61.1%;95%置信区间,53.0 - 68.7%),29名医生开始OCT治疗(18.5%;95%置信区间,12.9 - 25.6%)。134人认为应避免开始OCT治疗(85.3%;95%置信区间,78.6 - 90.3%),主要原因是监测困难、要求进一步检查困难、治疗存在风险以及OCT不够完善。

结论

大多数专业人员对NVAF患者的OCT标准明确,尽管他们仍避免开始OCT治疗。鉴于治疗风险以及监测和要求进一步检查的困难,大多数医生的做法是给予抗聚集药物并转诊至心脏病科。